The clinical study of beta 3-agonist (Betanis) for lower urinary tract symptoms mainly for overactive bladder

The clinical study of beta 3-agonist (Betanis) for lower urinary tract symptoms mainly for overactive bladder - The clinical study of beta 3-agonist for lower urinary tract symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008084

Enrollment

100

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower urinary tract symptoms (overactive bladder)

Interventions

beta 3-agonist

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) those who are diagnosed as OAB according to the OAB guideline (2) those who go urination more than 8 times per day, or who go urination more than 2 times at night (3) those who have incontinence more than 1 time per week

Exclusion criteria

Exclusion criteria: (1) those who have critical infectious disease or have uncontrollable complications (2) those who have active urothelial cancer or prostate cancer (3) those who have critical heart disease (4) those who have the episode of urinary retention (5) those who are considered as inappropriate for this study by the responsible doctor

Design outcomes

Primary

Measure	Time frame
safety, efficiency	—

Secondary

Measure	Time frame
I-PSS, OABSS	—

Countries

Japan

Contacts

Public ContactYoshio Sugino

Kyoto University Hospital Dept. of Urology

075-751-3337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026